BioSpace News Archive

Arcutis Biotherapeutics, Inc. announced that it has enrolled the first patient in Phase 1/2b study of ARQ-252, a potent and highly selective topical small molecule inhibitor of janus kinase type 1, in adult patients with chronic hand eczema.

OncoSec Medical Incorporated (“OncoSec”) (Nasdaq: ONCS), a company developing late-stage intratumoral cancer immunotherapies, today announced pre-clinical data from a feasibility study of its visceral lesion applicator (VLA) electroporation device and APOLLO generator which were presented online at the Annual Meeting of the Society of Interventional Radiology (SIR).

twoXAR Pharmaceuticals, a company that discovers drugs with AI, today announced that two novel leads for the potential treatment of systemic lupus erythematosus (SLE), TXR-711 and TXR-712, demonstrated significant efficacy and excellent tolerability in preclinical studies.

Arch Oncology, Inc., a clinical-stage immuno-oncology company focused on the discovery and development of best-in-class anti-CD47 antibody therapies, today announced the appointment of Julie Hambleton, M.D. to the Company’s Board of Directors.

Todos Medical Ltd. (OTCQB: TOMDF), a commercial in vitro diagnostics company focused on the development of blood tests for the early detection of cancer and neurodegenerative disorders, as well as point-of-care and lab-based tests for COVID-19, today announced that Gnomegen LLC (“Gnomegen”) has received Emergency Use Authorization (“EUA”) from the US Food & Drug Administration

OMRON, a global technology company, recently announced a series of cash and product donations to local charities through OMRON Foundation, its charitable arm in the United States, and through OMRON Healthcare, Inc.

Clarity Pharmaceuticals, a radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for 67Cu-SARTATE™, a therapy for the clinical management of neuroblastoma.

NellOne Therapeutics Inc., the early stage biopharmaceutical company using a talented protein to plot a new future for regenerative medicine, has appointed accomplished leader and entrepreneur William A. Malkes as its new Chief Executive Officer.

Murphy Medical Associates today announced it will be providing immunity testing for SARS CoV2 Immunoglobulins at www.CoronaTestCT.com.

Bio-Medical Devices, Intl (BMDI) has significantly ramped up MAXAIR® CAPR® production output in an effort to keep pace with the extreme demand for its highly preferred PAPRs (Powered Air Purifying Respirators), during the current COVID-19 pandemic.